Biofrontera reports financial results for the six months ended June 30, 2021
August 19, 2021 11:47 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera AG enters into exclusive license agreement with Maruho Co., Ltd.
April 20, 2020 04:20 ET
|
Biofrontera AG
Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, has...
Biofrontera shows robust growth during first six months of 2019
August 27, 2019 02:15 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera provides update on Cutanea integration
August 05, 2019 09:00 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...
Biofrontera provides information on the announced voluntary public tender offer by Maruho Deutschland GmbH
April 02, 2019 08:30 ET
|
Biofrontera AG
Leverkusen, Germany, April 02, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the...
Biofrontera AG and Maruho Co., Ltd. conclude cooperation agreement regarding branded generics and plan collaboration on expansion of indications and distribution of Ameluz®
March 19, 2019 07:42 ET
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today signed an agreement to...